Skip to content

Savara SVRA Research and development expense

Research and development expense at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
Mannkind logo
MannkindMNKD

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+247%
Enterprise value$1.19B+235%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's research and development expense?
Savara (SVRA) reported research and development expense of $23.4M in Q1 2026.
How has Savara's research and development expense changed year-over-year?
Savara's research and development expense increased by 22.1% year-over-year, from $19.16M to $23.4M.
What is the long-term trend for Savara's research and development expense?
Over 4 years (2021 to 2025), Savara's research and development expense has grown at a 29.4% compound annual growth rate (CAGR), from $28.99M to $81.4M.